Because SLC27A4 is a transmembrane protein, blockage of extracellular SLC27A4 via a SLC27A4 antibody might be a novel therapeutic strategy against breast cancer due to disruption of the SLC27A4/CD36-mediated fatty acids transportation pathway. The gene discussed is SLC27A4; the disease is breast carcinoma.